Literature DB >> 26080800

STAT3 activation is associated with cerebrospinal fluid interleukin-10 (IL-10) in primary central nervous system diffuse large B cell lymphoma.

Takashi Mizowaki1, Takashi Sasayama2, Kazuhiro Tanaka1, Katsu Mizukawa1, Kumi Takata1, Satoshi Nakamizo1, Hirotomo Tanaka1, Hiroaki Nagashima1, Masamitsu Nishihara3, Takanori Hirose4, Tomoo Itoh5, Eiji Kohmura1.   

Abstract

Signal transducers and activators of transcription 3 (STAT3) are activated by various cytokines and oncogenes; however, the activity and pathogenesis of STAT3 in diffuse large B cell lymphoma of the central nervous system have not been thoroughly elucidated. We investigated the phosphorylation levels of STAT3 in 40 specimens of primary central nervous system diffuse large B-cell lymphoma (PCNS DLBCL) and analyzed the association between phsopho-STAT3 (pSTAT3) expression and cerebrospinal fluid (CSF) concentration of interleukin-10 (IL-10) or IL-6. Immunohistochemistry and Western blot analysis revealed that most of the specimens in PCNS DLBCL expressed pSTST3 protein, and a strong phosphorylation levels of STAT3 was statistically associated with high CSF IL-10 levels, but not with CSF IL-6 levels. Next, we demonstrated that recombinant IL-10 and CSF containing IL-10 induced the phosphorylation of STAT3 in PCNS DLBCL cells. Furthermore, molecular subtype classified by Hans' algorithm was correlated with pSTAT3 expression levels and CSF IL-10 levels. These results suggest that the STAT3 activity is correlated with CSF IL-10 level, which is a useful marker for STAT3 activity in PCNS DLBCLs.

Entities:  

Keywords:  Central nervous system; Cerebrospinal fluid; Diffuse large B-cell lymphoma; IL-10; Prognosis; STAT3

Mesh:

Substances:

Year:  2015        PMID: 26080800     DOI: 10.1007/s11060-015-1843-9

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  26 in total

Review 1.  A meta-analysis of STAT3 and phospho-STAT3 expression and survival of patients with non-small-cell lung cancer.

Authors:  Y H Xu; S Lu
Journal:  Eur J Surg Oncol       Date:  2013-12-04       Impact factor: 4.424

2.  Expression of signal transducer and activator of transcription 3 (STAT3) in primary central nervous system diffuse large B-cell lymphoma: a retrospective analysis of 17 cases.

Authors:  Neerja Vajpayee; Juhi Hussain; Ioana Tolocica; Robert E Hutchison; Ajeet Gajra
Journal:  J Neurooncol       Date:  2010-05-06       Impact factor: 4.130

Review 3.  STAT3 as a central mediator of neoplastic cellular transformation.

Authors:  David A Frank
Journal:  Cancer Lett       Date:  2006-11-28       Impact factor: 8.679

4.  STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma.

Authors:  Anna Scuto; Maciej Kujawski; Claudia Kowolik; Ludmila Krymskaya; Lin Wang; Lawrence M Weiss; David Digiusto; Hua Yu; Stephen Forman; Richard Jove
Journal:  Cancer Res       Date:  2011-04-26       Impact factor: 12.701

5.  The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors.

Authors:  Michael Hedvat; Dennis Huszar; Andreas Herrmann; Joseph M Gozgit; Anne Schroeder; Adam Sheehy; Ralf Buettner; David Proia; Claudia M Kowolik; Hong Xin; Brian Armstrong; Geraldine Bebernitz; Shaobu Weng; Lin Wang; Minwei Ye; Kristen McEachern; Huawei Chen; Deborah Morosini; Kirsten Bell; Marat Alimzhanov; Stephanos Ioannidis; Patricia McCoon; Zhu A Cao; Hua Yu; Richard Jove; Michael Zinda
Journal:  Cancer Cell       Date:  2009-12-08       Impact factor: 31.743

6.  Frequent STAT3 activation is associated with Mcl-1 expression in nasal NK-cell lymphoma.

Authors:  M Tsutsui; H Yasuda; H Suto; H Imai; Y Isobe; M Sasaki; Y Kojima; K Oshimi; K Sugimoto
Journal:  Int J Lab Hematol       Date:  2009-11-24       Impact factor: 2.877

7.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.

Authors:  Christine P Hans; Dennis D Weisenburger; Timothy C Greiner; Randy D Gascoyne; Jan Delabie; German Ott; H Konrad Müller-Hermelink; Elias Campo; Rita M Braziel; Elaine S Jaffe; Zenggang Pan; Pedro Farinha; Lynette M Smith; Brunangelo Falini; Alison H Banham; Andreas Rosenwald; Louis M Staudt; Joseph M Connors; James O Armitage; Wing C Chan
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

Review 8.  STATs in cancer inflammation and immunity: a leading role for STAT3.

Authors:  Hua Yu; Drew Pardoll; Richard Jove
Journal:  Nat Rev Cancer       Date:  2009-11       Impact factor: 60.716

9.  STAT3 and MAPK in human lung cancer tissues and suppression of oncogenic growth by JAB and dominant negative STAT3.

Authors:  Yukio Seki; Noriko Suzuki; Munehisa Imaizumi; Takashi Iwamoto; Noriyasu Usami; Yuichi Ueda; Michinari Hamaguchi
Journal:  Int J Oncol       Date:  2004-04       Impact factor: 5.650

10.  The Immunohistochemical Expression of STAT3, Bcl-xL, and MMP-2 Proteins in Colon Adenoma and Adenocarcinoma.

Authors:  Seung Woo Lee; Young Yong Ahn; Yon Soo Kim; Sang Beum Kang; Soon Woo Nam; Dong Soo Lee; Hyun Yong Jeong; Jin Man Kim
Journal:  Gut Liver       Date:  2012-01-12       Impact factor: 4.519

View more
  6 in total

1.  Stat3-positive tumor cells contribute to vessels neoformation in primary central nervous system lymphoma.

Authors:  Simona Ruggieri; Roberto Tamma; Nicoletta Resta; Francesco Albano; Nicoletta Coccaro; Daria Loconte; Tiziana Annese; Mariella Errede; Giorgina Specchia; Rebecca Senetta; Paola Cassoni; Domenico Ribatti; Beatrice Nico
Journal:  Oncotarget       Date:  2017-05-09

Review 2.  Primary central nervous system lymphoma: clinicopathological and genomic insights for therapeutic development.

Authors:  Kensuke Tateishi; Yohei Miyake; Taishi Nakamura; Tetsuya Yamamoto
Journal:  Brain Tumor Pathol       Date:  2021-07-13       Impact factor: 3.298

3.  Biclustering-based association rule mining approach for predicting cancer-associated protein interactions.

Authors:  Lopamudra Dey; Anirban Mukhopadhyay
Journal:  IET Syst Biol       Date:  2019-10       Impact factor: 1.615

4.  Diagnostic markers for CNS lymphoma in blood and cerebrospinal fluid: a systematic review.

Authors:  Anouk van Westrhenen; Lisanne C A Smidt; Tatjana Seute; Stefan Nierkens; Abraham C J Stork; Monique C Minnema; Tom J Snijders
Journal:  Br J Haematol       Date:  2018-05-29       Impact factor: 6.998

Review 5.  Update on Novel Therapeutics for Primary CNS Lymphoma.

Authors:  Lauren R Schaff; Christian Grommes
Journal:  Cancers (Basel)       Date:  2021-10-26       Impact factor: 6.639

6.  Changes in cerebrospinal fluid interleukin-10 levels display better performance in predicting disease relapse than conventional magnetic resonance imaging in primary central nervous system lymphoma.

Authors:  Yan Zhang; Dongmei Zou; Jingjing Yin; Li Zhang; Xiao Zhang; Wei Wang; Meifen Zhang; Daobin Zhou; Wei Zhang
Journal:  BMC Cancer       Date:  2021-02-22       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.